Fujii, M.; Kobayakawa, M.; Saito, K.; Inano, A.; Morita, A.; Hasegawa, M.; Mukasa, A.; Mitsuhara, T.; Goto, T.; Yamaguchi, S.;
et al. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Curr. Oncol. 2021, 28, 726-739.
https://doi.org/10.3390/curroncol28010071
AMA Style
Fujii M, Kobayakawa M, Saito K, Inano A, Morita A, Hasegawa M, Mukasa A, Mitsuhara T, Goto T, Yamaguchi S,
et al. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Current Oncology. 2021; 28(1):726-739.
https://doi.org/10.3390/curroncol28010071
Chicago/Turabian Style
Fujii, Masazumi, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi,
and et al. 2021. "Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma" Current Oncology 28, no. 1: 726-739.
https://doi.org/10.3390/curroncol28010071
APA Style
Fujii, M., Kobayakawa, M., Saito, K., Inano, A., Morita, A., Hasegawa, M., Mukasa, A., Mitsuhara, T., Goto, T., Yamaguchi, S., Tamiya, T., Nakatomi, H., Oya, S., Takahashi, F., Sato, T., Bakhit, M., & on behalf of the BeatNF2 Trial Investigators.
(2021). Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma. Current Oncology, 28(1), 726-739.
https://doi.org/10.3390/curroncol28010071